LBA21 KEYNOTE-756: Phase III study of neoadjuvant pembrolizumab (pembro) or placebo (pbo) + chemotherapy (chemo), followed by adjuvant pembro or pbo + endocrine therapy (ET) for early-stage high-risk ER+/HER2– breast cancer

KEYNOTE-756 (NCT03725059) is a global phase 3 study of neoadjuvant pembro or pbo + chemo followed by adjuvant pembro or pbo + ET in patients (pts) with early-stage high-risk ER+/HER2– breast cancer. Here, we report primary pCR results.